Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Pembrolizumab & Non-small-cell lung cancer (NSCLC), on October 2, 2015, the FDA gave accelerated approval to pembrolizumab. It's a breakthrough therapy-designated drug. It's for patients with metastatic non-small cell lung cancer (NSCLC). Their tumors must express PD-L1. This is determined by an FDA-approved test. Patients should have disease progression after certain treatments. These include platinum-containing chemotherapy or targeted therapy. The approval came with t…